Healthcare generates massive volumes of data daily – from electronic health records and insurance claims to genomic research ...

On the forefront of healthcare change, turning innovative science into value for patients: Astellas at ASCO 2025 At this year ...

KalVista Pharma has finally received FDA approval for its oral kallikrein inhibitor sebetralstat, becoming the first ...

Medical research charities LifeArc and Genetics Alliance UK have issued a call to the government to topple obstacles impeding ...

President Donald Trump took time out from the 4th July celebrations in the US to sign his One Big, Beautiful Bill Act (OBBBA) ...

J&J has rights to niraparib in prostate cancer, and views the drug as a successor to Zytiga, once a $2.5 billion-a-year ...

The credit crunch has increased cost pressures on the pharmaceutical industry, Capgemini suggests that part of its response could be to open up a dialogue about the wider healthcare agenda. These ...

BIO 2025 brings pharma, biotech, and policy leaders together to tackle industry challenges. Follow our coverage on AI, vaccines, cell & gene therapy, and key discussions from health officials.

The most successful pharma sales teams will be those that define and service customers in new ways. Those who are the most responsive and relevant to today's customers and influencers will reap ...

Hannah Blake pharmaphorum Threshold Pharma is to go ahead with Phase 3 clinical trials of its only drug, TH-302, despite recent Phase 2 trials failing to show statistically significant improvement ...

Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.

Novo Nordisk's GLP-1 agonist semaglutide, used to treat diabetes and obesity, may cause a serious eye condition that can lead to the loss of vision, according to the EU medicines regulator. After ...